ABSTRACT
Published case series and systematic reviews have documented an association between bisphosphonates and osteonecrosis of the jaw. However, a cause-and- effect relationship has not been established, and most of the reported cases have been in patients with cancer who were receiving much higher doses than those used to treat osteoporosis or Paget disease of bone. The risk, if any, to patients with these latter conditions receiving these drugs appears to be very small.
Footnotes
↵a Dr. Carey has indicated that he has received honoraria, consulting fees, or both from Procter and Gamble; Merck, Sharp, and Dohme; and Novartis and has board membership in Merck, Sharp and Dohme and Novartis.
↵b Dr. Palomo has indicated that she has received research support from Procter and Gamble and Sanofi-Aventis.
- Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.